Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales
Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion.








